The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer worldwide, ranking as high as the second leading cause of cancer-related deaths in industrialized countries. Consistent with immunosurveillance theory, the immune system is crucial to protect the host from developing tumors, and the major players in tumoral immunity are effector T cells. Anyway, cancer cells develop strategies of immunoevasion influencing the cancer-specific lymphocyte priming, activation, and effector function. Therefore, the T cell subsets that mature during the stages of tumor growth, differently contribute to disease progression and/or regression. In our study, we analyzed the intra-tumoral and peripheral T cell subsets' distribution in 30 patients with CRC, in order to clarify their functional role toward cancer. We found that percentage of infiltrating effector T cells decreased in cancer tissue than in healthy mucosa and that the tumor microenvironment negatively influences the cytolytic activity of T lymphocytes reactive to cancer cells. Moreover, we found that the tumor tissue was infiltrated by a large amount of "not effector" T (neT) cells with a regulatory or an anergic profile, which are unable to kill cancer cells, may be contributing to the CRC promotion. The presence of neT cells was investigated also in the peripheral blood of CRC patients, demonstrating that the peripheral T regulatory cells can inhibit the proliferation of effector T cells, confirming their immunosuppressive properties. Finally, monitoring the changes in circulating neT cells' frequencies after the tumor removal, we confirmed the role of cancer in the modulation of immune system, in particular, in supporting a Tregs-mediated immunosuppression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 8(2017) vom: 16., Seite 1900 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Niccolai, Elena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitumor immune responses |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fimmu.2017.01900 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM280358792 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM280358792 | ||
| 003 | DE-627 | ||
| 005 | 20231226194726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2017.01900 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0934.xml |
| 035 | |a (DE-627)NLM280358792 | ||
| 035 | |a (NLM)29375559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Niccolai, Elena |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Colorectal cancer (CRC) is the third most common cancer worldwide, ranking as high as the second leading cause of cancer-related deaths in industrialized countries. Consistent with immunosurveillance theory, the immune system is crucial to protect the host from developing tumors, and the major players in tumoral immunity are effector T cells. Anyway, cancer cells develop strategies of immunoevasion influencing the cancer-specific lymphocyte priming, activation, and effector function. Therefore, the T cell subsets that mature during the stages of tumor growth, differently contribute to disease progression and/or regression. In our study, we analyzed the intra-tumoral and peripheral T cell subsets' distribution in 30 patients with CRC, in order to clarify their functional role toward cancer. We found that percentage of infiltrating effector T cells decreased in cancer tissue than in healthy mucosa and that the tumor microenvironment negatively influences the cytolytic activity of T lymphocytes reactive to cancer cells. Moreover, we found that the tumor tissue was infiltrated by a large amount of "not effector" T (neT) cells with a regulatory or an anergic profile, which are unable to kill cancer cells, may be contributing to the CRC promotion. The presence of neT cells was investigated also in the peripheral blood of CRC patients, demonstrating that the peripheral T regulatory cells can inhibit the proliferation of effector T cells, confirming their immunosuppressive properties. Finally, monitoring the changes in circulating neT cells' frequencies after the tumor removal, we confirmed the role of cancer in the modulation of immune system, in particular, in supporting a Tregs-mediated immunosuppression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a T helper | |
| 650 | 4 | |a antitumor immune responses | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a not effector T cells | |
| 650 | 4 | |a regulatory T cells | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 4 | |a tumor-infiltrating lymphocytes | |
| 700 | 1 | |a Ricci, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Edda |e verfasserin |4 aut | |
| 700 | 1 | |a Nannini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Taddei, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ringressi, Maria Novella |e verfasserin |4 aut | |
| 700 | 1 | |a Melli, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Miloeva, Manouela |e verfasserin |4 aut | |
| 700 | 1 | |a Cianchi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Bechi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Prisco, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Amedei, Amedeo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 8(2017) vom: 16., Seite 1900 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g day:16 |g pages:1900 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2017.01900 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |b 16 |h 1900 | ||